Superpower peptides available for pre-order. Get first access.

Peptide science

What are the side effects of PE-22-28?

No Phase 1 study has tested PE-22-28, so its side effects in people are unknown. Rodent TREK-1 findings, product risks, and who should be most cautious.

Quick answer

PE-22-28 has no documented side effects in people because no Phase 1 study has tested it. ClinicalTrials.gov listed no human trials of PE-22-28 or its parent peptide, spadin, on November 12, 2026. In mice lacking its target, TREK-1, blood-brain barrier damage after a brain bleed was worse, but strokes after ischemia were smaller. Online vials are unverified, and PE-22-28 is not approved.

Published
November 12, 2026
Last updated
November 12, 2026

PE-22-28 has no documented human side effects

PE-22-28 side effects in people have never been documented. No Phase 1 study has tested the peptide. No human study of PE-22-28 or its parent peptide spadin is registered on ClinicalTrials.gov as of November 12, 20261. Rodent work on PE-22-28's target points in both directions, leaving the human risk unresolved.

Without human safety data, every claim about PE-22-28's side effects is an inference. The published record is cell and mouse experiments2, and the wider spadin program stops at preclinical optimization3. Tolerability is first measured in a Phase 1 study. Across 394 such studies, 63.7% of healthy participants given the drug4 had at least one adverse event.

Four questions stay open:

Animal data do not fill that gap. Across 108 drugs in early cancer trials, animal toxicity predicted human toxicity poorly8. The median positive predictive value, the share of animal toxicity signals that also appeared in people, was 0.65. That limit applies to every rodent finding on PE-22-28's target.

Rodent TREK-1 findings point in opposite directions

Removing TREK-1 harmed mice after one kind of brain injury and helped them after another. Mice without the channel had worse blood-brain barrier damage after a brain bleed9. The same deletion gave mice smaller strokes and less neuronal death10 after a blocked artery. Earlier work found knockout mice more sensitive to ischemia and epilepsy11.

None of those studies tested PE-22-28, and deleting a gene is not the same as blocking a channel with a peptide. The one in vivo study to give the PE-22-28 sequence after a stroke reported protective effects. Its electrophysiology showed a biphasic action on TREK-112, activity rising at low doses and falling at higher ones. Rodents given spadin, the parent peptide, showed no change in stroke size, seizures, or heart function13. Dose and injury type both change the direction, and neither has been mapped in people. Product quality adds a separate layer of risk.

Unregulated vials carry risks of their own

PE-22-28 sold online is made outside drug-quality oversight, so identity, purity, and sterility rest on the seller's word. FDA verifies a drug's safety, effectiveness, and quality through its approval process14, and PE-22-28 is not FDA-approved.

Testing of another peptide, semaglutide, shows how far vial contents can stray from the label. Three vials bought online without a prescription measured 7.7% to 14.37% purity15 against a 99% label claim. Every sample also contained endotoxin, a toxin from bacterial cell walls. A companion report on the same purchases16 reached the same conclusion. Contaminated injectable vials from one compounding pharmacy caused 749 infections and 61 deaths17. None of these studies involved PE-22-28, and only the first two looked at online sellers.

Who has the most reason for caution

Five groups carry more theoretical risk from PE-22-28 than others, though nobody outside an approved research study has a safety basis for taking it. None of these is a recorded effect, because no data in people exist.

Caution here rests on biology and missing data rather than on a known harm.

Where can I learn about peptides?

Separating what a mouse study showed from what a seller implies is most of the work with a preclinical compound. Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians.

PE-22-28 is one short fragment acting on one potassium channel. The science behind peptides explains how sequences like it are built and tested.

IMPORTANT SAFETY INFORMATION

PE-22-28 is not approved by the FDA for any medical use. Published research on this compound is limited to cell and animal studies, and no human clinical trial has been registered. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. PE-22-28 is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

There are no human clinical safety data for PE-22-28. Its side effect profile, tolerability, immunogenicity, drug interactions, and pharmacokinetics in humans are unknown. Rodent findings on its target, TREK-1, point in opposite directions depending on the injury model and cannot be used to characterize human risk.

PE-22-28 should not be used by anyone outside an IRB-approved clinical research study. No approved label exists, so no formal contraindications exist. Populations of particular theoretical concern include: people with a history of stroke, brain bleeding, or other cerebrovascular disease (rodent TREK-1 findings differ by injury type); people taking medications that act on serotonin (interactions have not been studied); pregnant or breastfeeding individuals (no reproductive or developmental data exist); and people under active psychiatric care. These are illustrative concerns, not a contraindication checklist.

Products sold online as PE-22-28 are unregulated. They are not subject to FDA oversight, cGMP manufacturing standards, or identity, purity, and sterility verification. Contamination, dosing inconsistency, and mislabeled contents are documented risks of unregulated peptide products.

The World Anti-Doping Agency's Prohibited List class S0 covers substances not approved by any governmental regulatory health authority for human therapeutic use, including drugs in preclinical development. Competitive athletes should note that an unapproved compound falls within that description.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to PE-22-28. PE-22-28 is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science